Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
replicative/JJ
gene/NN
expression/NN
in/IN
tumour/NN
cells/NNS
of/IN
AIDS-related/JJ
non-Hodgkin/JJ
's/POS
lymphoma/NN
in/IN
relation/NN
to/TO
CD4/NN
cell/NN
number/NN
and/CC
antibody/NN
titres/NNS
to/TO
EBV/NN
./.

OBJECTIVE/NN
:/:
To/TO
determine/VB
whether/IN
activation/NN
of/IN
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
replication/NN
in/IN
tumour/NN
cells/NNS
of/IN
AIDS-related/JJ
non-Hodgkin/JJ
's/POS
lymphoma/NN
(/(
ARNHL/NN
)/)
is/VBZ
correlated/VBN
with/IN
CD4+/JJ
cell/NN
counts/NNS
and/CC
influences/VBZ
antibody/NN
response/NN
to/TO
EBV/NN
[/(
anti-Z/JJ
Epstein-Barr/JJ
replicative/JJ
activator/NN
(/(
ZEBRA/NN
)/)
,/,
anti-early/JJ
antigen/NN
(/(
EA/NN
)/)
,/,
anti-viral/JJ
capsid/NN
antigen/NN
(/(
VCA/NN
)/)
]/)
./.
=====
DESIGN/NN
:/:
Retrospective/JJ
study/NN
based/VBN
on/IN
immunohistochemistry/NN
and/CC
in/FW
situ/FW
hybridization/NN
to/TO
detect/VB
EBV/NN
replicative/JJ
gene/NN
products/NNS
in/IN
tissue/NN
samples/NNS
from/IN
patients/NNS
affected/VBN
by/IN
ARNHL/NN
and/CC
correlation/NN
with/IN
CD4+/JJ
cell/NN
counts/NNS
and/CC
results/NNS
of/IN
EBV/NN
serology/NN
(/(
including/VBG
anti-ZEBRA/JJ
activity/NN
)/)
in/IN
sera/NNS
from/IN
the/DT
same/JJ
patients/NNS
./.
=====
METHODS/NNS
:/:
Seventeen/CD
out/IN
of/IN
22/CD
cases/NNS
of/IN
ARNHL/NN
were/VBD
selected/VBN
for/IN
the/DT
presence/NN
of/IN
EBV/NN
[/(
Epstein-Barr/JJ
early/JJ
region/NN
(/(
EBER/NN
)/)
RNA-positive/JJ
]/)
./.
=====
Immunohistochemistry/NN
was/VBD
performed/VBN
with/IN
anti-ZEBRA/JJ
,/,
anti-EA-restricted/JJ
,/,
anti-VCA/JJ
antibodies/NNS
and/CC
in/FW
situ/FW
hybridization/NN
with/IN
BHLF1/NotI/NN
oligoprobes/NNS
on/IN
tumour/NN
samples/NNS
./.
=====
Results/NNS
were/VBD
statistically/RB
correlated/VBN
with/IN
those/DT
of/IN
CD4+/JJ
cell/NN
counts/NNS
(/(
17/CD
out/IN
of/IN
17/CD
)/)
and/CC
with/IN
anti-EBV/JJ
antibody/NN
titres/NNS
(/(
13/CD
out/IN
of/IN
17/CD
)/)
assessed/VBN
using/VBG
standard/JJ
immunofluorescence/NN
method/NN
and/CC
enzyme-linked/JJ
immunosorbent/JJ
assay/NN
procedure/NN
using/VBG
recombinant/JJ
ZEBRA/NN
protein/NN
and/CC
synthetic/JJ
peptides/NNS
as/IN
antigens/NNS
./.
=====
RESULTS/NNS
:/:
BZLF1/NN
(/(
ZEBRA/NN
)/)
or/CC
early/JJ
gene/NN
products/NNS
(/(
EA-R/NN
and/CC
EA-D/BHLF1/NotI/NN
)/)
were/VBD
detected/VBN
in/IN
a/DT
small/JJ
proportion/NN
(/(
</JJR
0.01-5/CD
%/NN
)/)
of/IN
tumour/NN
cells/NNS
in/IN
eight/CD
of/IN
these/DT
17/CD
cases/NNS
by/IN
immunohistochemistry/NN
and/CC
in/FW
situ/FW
hybridization/NN
./.
=====
Demonstration/NN
of/IN
replicative/JJ
gene/NN
expression/NN
did/VBD
not/RB
correlate/VB
with/IN
either/CC
low/JJ
CD4+/JJ
cell/NN
counts/NNS
(/(
P/NN
>/JJR
0.05/CD
)/)
or/CC
anti-EBV/JJ
antibody/NN
titres/NNS
(/(
P/NN
>/JJR
0.05/CD
)/)
./.
=====
Anti-ZEBRA/JJ
activity/NN
was/VBD
not/RB
significantly/RB
increased/VBN
in/IN
patients/NNS
affected/VBN
with/IN
ARNHL/NN
,/,
the/DT
cells/NNS
of/IN
which/WDT
expressed/VBD
replicative/JJ
gene/NN
products/NNS
(/(
P/NN
>/JJR
0.05/CD
)/)
./.
=====
CONCLUSION/NN
:/:
The/DT
degree/NN
of/IN
immunodeficiency/NN
does/VBZ
not/RB
clearly/RB
enhance/VB
replicative/JJ
gene/NN
expression/NN
in/IN
tumour/NN
cells/NNS
of/IN
ARNHL/NN
./.
=====
EBV/NN
serology/NN
,/,
including/VBG
anti-ZEBRA/JJ
activity/NN
,/,
is/VBZ
not/RB
a/DT
reliable/JJ
tool/NN
for/IN
predicting/VBG
the/DT
occurrence/NN
of/IN
such/JJ
proliferations/NNS
./.